The money question behind the pipelines
On October 30, 2026, a $1 trillion tech selloff deepened fears of an AI bubble, and the Nasdaq 100 had its worst day since June.1 The next day, OpenAI cut its funding target by $10 billion.2 On November 1, Binance users withdrew $3.6 billion when the exchange reopened after a hack.3 None of these events involves a drug. But they set the price of money for every company that has no product revenue yet, and that is most of the small biotechs now reporting results.
The question for an investor is simple. Who can keep funding trials until the data arrives? The dossier we hold has one company with a deep, SEC-checked financial record, Incyte, so we use it as the yardstick. For the small names it carries milestones and guidance but few audited numbers. We say so where that matters.
What a funded balance sheet looks like: Incyte
Incyte is a commercial-stage company, so it is not a like-for-like peer for a pre-revenue biotech. Its cash history is useful for a different reason: it shows how much a cash balance can move in a year.
Incyte held $3.21 billion in cash at the end of fiscal 2023.4 By the end of fiscal 2024 that was $1.69 billion.4 The quarterly record shows the path: $3.35 billion in Q1 2024, then $987 million in Q2 2024, then $1.30 billion in Q3 2024.4 Our dossier does not say what caused the drop, so we will not guess. The point is that a large biotech's cash fell by roughly half within a year and then recovered.
Fiscal 2025 closed at $3.10 billion.4 The 2026 quarters read $3.46 billion (Q1), $3.98 billion (Q2) and $3.28 billion (Q3).4 To picture the scale, Q3 2026 cash is roughly nine times Incyte's entire fiscal 2025 cost of revenue of $372 million.5 (That ratio is Via News arithmetic on two verified figures.) It is also close to the $3.6 billion that left Binance in a day.3
Cost of revenue, the direct cost of making what Incyte sells, has climbed steadily: $255 million in fiscal 2023, $312 million in fiscal 2024 and $372 million in fiscal 2025.5 Quarterly figures show the pace slowing. Q1 2026 was $104.5 million against $73.2 million a year earlier. Q2 2026 was $105.0 million against $78.8 million. Q3 2026 was $108.7 million against $99.0 million.5 By our arithmetic that is growth of about 43%, 33% and 10% year on year. Sales figures are not in our dossier, so we cannot say whether margins moved. A falling growth rate in cost alone is not good or bad news.
One caution on data quality. Capital spending is recorded as exactly $48.7 million for both fiscal 2024 and fiscal 2025.6 Identical figures in consecutive years can be coincidence or a data artefact. We present it as filed and would not build a conclusion on it. Fiscal 2023 earnings per share were $2.65.7
The dossier's entity record links Incyte to Jakafi, Opzelura, pemigatinib and a candidate called INCB186748, and shows a licence to Dermavon Holdings Limited. The topic also names partnerships with BMS and Synnovation, but our dossier holds no deal terms for them. We therefore cannot say how much those deals contribute to Incyte's cash.
The small caps: milestones, not yet audited runways
The smaller companies each give the market a date to hold them to. Our dossier does not contain their cash balances, so this section shows what they have promised, not whether they can pay for it.
Scribe Therapeutics reported Q3 2026 results on November 12. It lists on Nasdaq under SCTX and has raised capital to fund the initial development of STX-1150, STX-1200 and STX-1400. Its first-in-human trial of STX-1150, an epigenetic silencing therapy for LDL cholesterol, is still enrolling, with initial data expected in the first half of 2027. It also expanded its collaboration with Sanofi.8 Scribe argues that current LDL-C therapies suffer from poor persistence, with studies showing 50% to 70% of patients stop within a year.8 It says naturally occurring PCSK9 loss-of-function variants are linked to 28% lower mean LDL-C and up to 88% lower coronary heart disease risk, and that STX-1150 aims to mimic that protection.8 These are the company's own statements, not independent findings.
Vor Bio announced final two-year Phase 3 results for telitacicept in IgA nephropathy. The annualised kidney-function decline was -0.6 against -5.7 mL/min/1.73 m² for placebo, a 5.1 difference (p<0.001), with 89% and 81% reductions in the risk of confirmed 30% and 40% declines.9 This is the strongest clinical result in our material, and it is also company-reported.
Akari Therapeutics plans Phase 1 development of AKTX-101 in mid-2027.10 Its position, in the company's words, is that patients whose cancers stopped responding to antibody drug conjugates are an unmet need and an exclusive opportunity for its novel payload.10 Ernexa says it remains on schedule to file its IND for ERNA-101 in the third quarter of 2026, with a first-in-human Phase 1 trial in the fourth quarter.11 Prelude guided to an IND for PRT13722 by mid-2026 and a Phase 1 start in ER-positive breast cancer in the second half of 2026.12 Both of those dates are already behind us or close. Our dossier does not confirm whether they were met, and that is the first thing to check. OPKO reported that its candidate OPK8801001 showed about 20-fold greater growth hormone receptor antagonism than Pegvisomant in vitro, meaning in a lab dish, not in patients.13
The royalty anchor: BioArctic
Not every biotech in this story is pre-revenue. BioArctic receives a royalty on Leqembi, sold through its partner Eisai. Eisai reported Leqembi sales of JPY 29.3 billion for Q2 2026, which produced a royalty to BioArctic of SEK 179 million, up about 10% on Q2 2025.14 The headline understates the trend. Q2 2025 included a one-time Chinese stockpiling effect of around JPY 5.3 billion, and excluding it, BioArctic says, royalty revenues grew approximately 43%.14 The company's own wording is: "Excluding the stockpiling effect, royalty revenues in Q2 2026 grew approximately 43 percent compared to the same quarter last year."14 This is what a royalty stream does for a small company: it funds the lab while the market is shut to new equity.
AI-bio: real firsts, thin evidence
Radical Numerics says AI-designed viruses have treated its first patient, in an experimental treatment for drug-resistant E. coli.15 That is a first-patient milestone, not an efficacy result, and our dossier contains no trial data to weigh it. Treat it as a demonstration stage.
A separate warning on source quality. A longevity startup, Generation Lab, says its treatment "blocks the systemic spread of aging in the bloodstream, reawakens the body's own repair mechanism and restores health and youth to multiple tissues."16 That is a marketing claim, quoted as such. The MIT Technology Review items that carried it score 6% on our measured reliability, with 6% of 16 checked claims holding up. That is a small sample, but it is a reason for caution, not a reason for confidence.
How reliable are the sources?
The company press releases above come through NewsEOD, where 54% of 6,692 checked claims held up. That is a coin flip, so numbers from press releases deserve independent confirmation against filings. The Motley Fool comparison of AbbVie and Eli Lilly, cited in the topic's reference to Lilly's weight-loss demand, scores 31% of 58 claims.17 Our dossier carries no Lilly figures we can verify, so we make no claim about Lilly's numbers. Only the Incyte figures here are checked against SEC filings.
What to watch
- Whether Prelude and Ernexa filed their INDs on the dates they guided, since the dossier cannot confirm it.
- Scribe's first STX-1150 data in the first half of 2027, and its next quarterly cash disclosure.
- Akari's mid-2027 Phase 1 start.
- Incyte's next quarter: cost of revenue growth slowed to about 10% year on year in Q3 2026, and cash fell from $3.98 billion to $3.28 billion over the quarter.
- Further moves in the tech funding market, since OpenAI's cut and the selloff are the clearest signs that capital is tightening.
Our read, as Via News analysis and not verified data: the sector is splitting into companies that can fund themselves, through royalties or large balance sheets, and companies that depend on the next raise. The evidence for this is indirect, and company cash runways are the number to find before buying any small cap named here.

